NasdaqCM:VKTXBiotechs
Viking Therapeutics (VKTX) Reports Increased Net Losses For Second Quarter
Viking Therapeutics (VKTX) recently announced promising Phase 2 clinical trial results for VK2735, which showcases significant body weight reductions and a favorable safety profile. Despite this positive development, the company reported a substantial increase in net losses for the second quarter. Over the last quarter, the company's share price decreased by 4.89%. This movement echoes broader market trends as the S&P 500 fell slightly during the same period. The juxtaposition of clinical...